69.65
+0.4(+0.58%)
Currency In HKD
Sector
Healthcare
Industry
Biotechnology
Employees
665
First IPO Date
October 09, 2020
| Name | Title | Pay | Year Born |
| Mr. Yongqing Luo | Chief Executive Officer & Executive Director | 32.6M | 1970 |
| Mr. Ian Ying Woo | Chief Financial Officer, President & Executive Director | 16.31M | 1973 |
| Ms. Sandra Zeng | Chief Medical Officer | 0 | 1967 |
| Mr. Fu Wei | Executive Chairman | 0 | 1983 |
| Ms. Yee Wa Lau | Joint Company Secretary | 0 | 1973 |
| Ms. Leah Liu | Joint Company Secretary & Vice President of Investor Relations | 0 | N/A |
| Mr. Chonggang Xu Steve | Chief Legal & Compliance Officer | 0 | 1969 |
| Mr. Xu Liang Rico | Chief Product Officer | 0 | 1969 |
| Dr. Jason M. Brown Ph.D. | Chief Business Officer | 0 | 1973 |
| Dr. Wei Yang Ph.D. | Chief Scientific Officer | 0 | 1970 |
Everest Medicines Limited, a biopharmaceutical company, engages in discovery, licensing, clinical development, and commercialization of therapies to address critical unmet medical needs in Greater China and other Asia Pacific markets. Its pipeline products include eleven clinical-stage drug candidates for the treatment of oncology, immunology, cardio-renal, and infectious diseases. Everest Medicines Limited was incorporated in 2017 and is headquartered in Shanghai, China.